Table 2.
Histopathological, immunohistochemical, and genetic features of 21 cases of pediatric sclerosing rhabdomyosarcomas.
| Year | Author | Age/ Sex |
Vimentin | Desmin | Myogenin (myf4) | MyoD1 | SMA | Cytokeratin | S100 | CD99 | Amount of fibrosis | Rhabdo-myoblasts | Mitoses | PAX3/FXHR by RT-PCR | Karyotype |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2002 | Folpe et al. [8] | 18/M | NA | Focally (+) | Focally (+) | Strongly (+) | 3+ | Neg. | Neg. | Neg. | Abundant | (−) | >25/20 HPF | NA | NA |
|
| |||||||||||||||
| 2004 | Vadgama et al. [9] | 3/F | Strongly (+) | Strongly (+) | Focally (+) | Strongly (+) | Focally (+) | Neg. | Neg. | Focally (+) | Dense | (−) | 32/100 HPF | Neg. | NA |
|
| |||||||||||||||
| 2004 | Chiles et al. [7] | 6/M | NA | Pos. | Pos. | Pos. | NA | NA | NA | NA | >50% | (−) | NA | NA | NA |
| 11/M | NA | NA | NA | NA | NA | NA | NA | NA | 10–50% | (−) | NA | Neg. | CK | ||
| 7/F | NA | Focally (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | NA | NA | ||
| 10/F | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | ||
| 3/M | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Pos. | NA | ||
| 8/F | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | NA | NA | ||
| 16/F | NA | Focally (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | ||
| 4/F | NA | Strongly (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | ||
| 12/M | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | ||
| 9/M | NA | Focally (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | CK | ||
| 4/M | NA | Strongly (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | ||
| 0.3/M | NA | Focally (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | ||
| 5/M | NA | Strongly (+) | Focally (+) | Focally (+) | NA | NA | NA | NA | >50% | (+) | NA | Neg. | NA | ||
|
| |||||||||||||||
| 2006 | Zambrano et al. [11] | 8/F | NA | Strongly (+) | Focal (+) | Focally (+) | Focally (+) | NA | Neg. | Neg. | Abundant | (−) | Numerous | Neg. | NK |
| 18/M | NA | Strongly (+) | Weakly (+) | Strongly (+) | Strongly (+) | NA | Neg. | Weakly (+) | Abundant | (−) | Numerous | Neg. | CK | ||
| 17/F | NA | Focally (+) | Focally (+) | Focally (+) | Focally (+) | NA | Neg. | Weakly (+) | Abundant | (+) | Numerous | Neg. | CK | ||
|
| |||||||||||||||
| 2008 | Wang et al. [10] | 12/F | Strongly (+) | Focally (+) | Focally (+) | Strongly (+) | Focally (+) | NA | Pos. | NA | Abundant | (−) | 5/10 HPF | NA | NA |
|
| |||||||||||||||
| 2009 | Bouron-Dal Soglio et al. [6] | 7/M | NA | Strongly (+) | Focally (+) | NA | NA | NA | NA | NA | Abundant | (−) | NA | Neg. | CK |
|
| |||||||||||||||
| 2013 | Present case | 11/M | Strongly (+) | Strongly (+) | Focal (+) | Not done | Neg. | Neg. | Neg. | Neg. | Abundant | (−) | NA | Not done | Not done |
NA: not available; Neg.: negative; Pos.: positive; HPF: high power field; CK: complex karyotype; NK: normal karyotype.